MHTP Technology Platforms are an integral component of the MHTP research strategy, providing cutting edge capabilities and expertise to support research within the Precinct.Each Platform recently underwent a review to ensure alignment with current research resulting in several rationalisation strategies and actions have now been endorsed by executive management.
The following changes to services will take affect in early 2019:
1. Sanger Sequencing, Fragment Analysis, Microarray and Cell Line ID services will cease on March 31st 2019.
This primarily stems from Life Technologies and Agilent's decision to no longer support the ageing model of instruments (our 3130xl will be 14 years old and Scanner, 16 years old).
Monash University's Micromon service can provide internal pricing, so there will be minimum change in charges.
Turn around time will be 48 hours for sequencing and electrophoresis and transport arrangements are presently being confirmed.
2. Quantstudio 6 (low throughput qPCR) services will be merged with the BioMark (high throughput qPCR) service by March 31st 2019.
The BioMark instrument will operate under a 'Do-It-Yourself' access mode following training and induction (i.e in line with use of the current Quantstudio 6 systems).
Real Time PCR reagents will be purchased through the Hudson store via the intranet page as of January 03rd 2019 and not available through the Platform.
3. Diagnostic Mass Spectrometry capabilities will be relocated to Monash Pathology by March 31st 2019.
Remembering, Hudson Institute has a subscription to access instruments in Bio21 and support through the Monash Biomedical Proteomics Facility is also available.
For further information, contact Vivien Vasic (vivien.vasic@hudson.org.au).
No comments:
Post a Comment